We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-8.03%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$141M
AUM Growth
-$177M
(-56%)
Cap. Flow
-$166M
Cap. Flow
% of AUM
-117.42%
Top 10 Holdings %
Top 10 Hldgs %
60.47%
Holding
47
New
9
Increased
2
Reduced
14
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$7.43M |
| 2 |
Labcorp
LH
|
+$6.59M |
| 3 |
Amgen
AMGN
|
+$4.67M |
| 4 |
ATHN
Athenahealth, Inc.
ATHN
|
+$4.41M |
| 5 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$4.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ELGX
Endologix Inc
ELGX
|
+$35.7M |
| 2 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$24.7M |
| 3 |
NXTM
NxStage Medical Inc.
NXTM
|
+$17.5M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$16M |
| 5 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.44% |
| 2 | Industrials | 3.05% |
| 3 | Consumer Discretionary | 2.51% |
| 4 | Communication Services | 0% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $10.6M | 7.48% |
850,000
-1,000,000
| -54% | -$12M |
|
|
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
| $9.64M | 6.82% |
367,690
-707,310
| -66% | -$17.5M |
|
|
HOLX
3
DELISTED
Hologic
HOLX
| $9.23M | 6.53% |
230,000
-160,000
| -41% | -$6.17M |
|
4
Bio-Rad Laboratories Class A
BIO
$10.3B
| $8.93M | 6.32% |
49,000
-59,000
| -55% | -$10.1M |
|
5
Pacira BioSciences
PCRX
$1.05B
| $8.82M | 6.24% |
273,000
-127,000
| -32% | -$4.24M |
|
6
Jazz Pharmaceuticals
JAZZ
$16B
| $8.39M | 5.94% |
77,000
-23,000
| -23% | -$2.56M |
|
|
SPNC
7
DELISTED
Spectranetics Corp
SPNC
| $8.07M | 5.71% |
329,600
-170,400
| -34% | -$4.01M |
|
|
MDRX
8
DELISTED
Veradigm Inc. Common Stock
MDRX
| $7.81M | 5.53% |
765,000
-520,000
| -40% | -$5.93M |
|
|
9
Gilead Sciences
GILD
$187B
| $7.16M | 5.07% |
+100,000
| New | +$7.43M |
|
10
Teladoc Health
TDOC
$1.14B
| $6.86M | 4.85% |
415,600
+90,600
| +28% | +$1.54M |
|
|
11
Labcorp
LH
$26.5B
| $6.55M | 4.63% |
+59,364
| New | +$6.59M |
|
12
NovoCure
NVCR
$2.09B
| $6.48M | 4.58% |
825,000
+50,000
| +6% | +$402K |
|
|
CORV
13
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $5.04M | 3.56% |
1,825,000
-375,000
| -17% | -$1.07M |
|
|
HIND
14
Vyome Holdings
HIND
$15.6M
| – | – |
0
| – | – |
|
|
15
Amgen
AMGN
$236B
| $4.53M | 3.21% |
+31,000
| New | +$4.67M |
|
16
Alkermes
ALKS
$7.73B
| $4.33M | 3.07% |
78,000
-147,000
| -65% | -$7.86M |
|
|
ATHN
17
DELISTED
Athenahealth, Inc.
ATHN
| $4.31M | 3.05% |
+41,000
| New | +$4.41M |
|
18
Steris
STE
$21.9B
| $4.25M | 3% |
63,000
-157,000
| -71% | -$10.6M |
|
19
Service Corp International
SCI
$11.2B
| $3.55M | 2.51% |
+125,000
| New | +$3.33M |
|
|
IPXL
20
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.41M | 2.41% |
+257,500
| New | +$4.4M |
|
|
CORI
21
DELISTED
Corium International, Inc.
CORI
| $2.99M | 2.12% |
737,242
-327,758
| -31% | -$1.64M |
|
|
LMNX
22
DELISTED
Luminex Corp
LMNX
| $2.73M | 1.93% |
135,000
-325,000
| -71% | -$6.77M |
|
|
STRM
23
DELISTED
Streamline Health Solutions
STRM
| $1.42M | 1.01% |
75,867
| – | – |
|
24
Boston Scientific
BSX
$69.3B
| $635K | 0.45% |
+2,200
| New | +$48K |
|
|
QTNT
25
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $484K | 0.34% |
2,500
-16,250
| -87% | -$3.51M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2016 Portfolio in Review
As of Q4 2016, Tamarack Advisers held 47 positions worth $141M, down 56% from $318M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Tamarack Advisers withdrew a net $166M in Q4 2016, closing 20 positions and reducing 14 holdings. Its most notable exit was Endologix Inc, an estimated $35.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Gilead Sciences worth $7.16M.
- Tamarack Advisers's largest Q4 2016 buy was Gilead Sciences: 100,000 shares worth $7.16M.
- Tamarack Advisers added most to Teladoc Health in Q4 2016, an estimated $1.54M increase.
- Tamarack Advisers's biggest Q4 2016 reduction was NxStage Medical Inc., cutting an estimated $17.5M.
- Tamarack Advisers fully exited Endologix Inc in Q4 2016, selling an estimated $35.7M.
- Tamarack Advisers's ten largest holdings make up 60% of its $141M portfolio in Q4 2016.
- Tamarack Advisers opened 9 new positions and closed 20 in Q4 2016.
- Tamarack Advisers's portfolio value fell 56% quarter-over-quarter to $141M.
Based on Tamarack Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.